- Trials with a EudraCT protocol (1,307)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,307 result(s) found for: Bone scan.
Displaying page 5 of 66.
EudraCT Number: 2013-004055-20 | Sponsor Protocol Number: ICR-CTSU/2013/10040 | Start Date*: 2014-09-23 | ||||||||||||||||
Sponsor Name:The Royal Marsden NHS Foundation Trust [...] | ||||||||||||||||||
Full Title: A phase II randomised trial of biomarkers to assess (dose-) response in patients with metastatic castration resistant prostate cancer treated with radium-223. | ||||||||||||||||||
Medical condition: Castrate resistant prostate cancer with bone metastases. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-003402-40 | Sponsor Protocol Number: XL184-401 | Start Date*: 2015-06-16 | |||||||||||
Sponsor Name:Exelixis, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients | |||||||||||||
Medical condition: Progressive Metastatic Medullary Thyroid Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) SE (Completed) ES (Ongoing) FR (Completed) PL (Trial now transitioned) HU (Trial now transitioned) HR (Trial now transitioned) IT (Completed) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002814-38 | Sponsor Protocol Number: SP005 | Start Date*: 2013-09-27 | |||||||||||
Sponsor Name:SOTIO a.s. | |||||||||||||
Full Title: A Randomized, Double Blind, Multicenter, Parallel-group, Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer elig... | |||||||||||||
Medical condition: metastatic castrate-resistant prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) DE (Completed) BE (Completed) CZ (Completed) IT (Completed) NL (Completed) ES (Completed) HU (Completed) PT (Completed) BG (Completed) SK (Completed) PL (Completed) HR (Completed) AT (Completed) LV (Completed) LT (Completed) DK (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003227-20 | Sponsor Protocol Number: ZD4054 | Start Date*: 2007-09-27 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III, Randomised, Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free... | |||||||||||||
Medical condition: hormone-resistant prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FI (Prematurely Ended) DE (Completed) BE (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) NL (Completed) FR (Completed) PT (Completed) DK (Prematurely Ended) HU (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005294-60 | Sponsor Protocol Number: CRAD001C24114 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: Multicenter, triple-arm, single-stage, phase II trial to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or soft tis... | |||||||||||||
Medical condition: histological evidence of progressive or metastatic bone or soft tissue sarcomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005398-73 | Sponsor Protocol Number: 2007-005398-73 | Start Date*: 2008-06-04 | |||||||||||
Sponsor Name:Karolinska University Hospital | |||||||||||||
Full Title: Treatment of malignant mesothelioma with pemetrexed (Alimta) + platinum (4 courses) or pemetrexed (Alimta) + platinum (4 courses) followed by Caelyx single drug (4 courses). | |||||||||||||
Medical condition: Malignant pleural mesotelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003023-38 | Sponsor Protocol Number: CHUBX2017/47 | Start Date*: 2019-12-20 | |||||||||||
Sponsor Name:CHU de Bordeaux | |||||||||||||
Full Title: Imaging with 68Ga-DOTA-peptides and peptide receptor radionuclide therapy with 177Lu-DOTA-peptides of gastroenteropancreatic neuroendocrine tumors: interest of intra-arterial hepatic infusion in pa... | |||||||||||||
Medical condition: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000931-15 | Sponsor Protocol Number: ICR-CTSU/2016/10060 | Start Date*: 2018-07-02 |
Sponsor Name:Institute of Cancer Research | ||
Full Title: PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab For Patients Suffering from Metastatic Prostate Cancer. | ||
Medical condition: Metastatic Castration Resistant Prostate Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2010-018662-23 | Sponsor Protocol Number: C21005 | Start Date*: 2010-10-14 | |||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK 700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Th... | |||||||||||||
Medical condition: Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or Following Docetaxel-based Therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) EE (Completed) BE (Completed) SK (Completed) SE (Completed) FI (Completed) LT (Completed) NL (Completed) CZ (Completed) ES (Completed) AT (Completed) GB (Completed) PT (Completed) IE (Completed) GR (Completed) DE (Completed) IT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004397-99 | Sponsor Protocol Number: MBCC28040 | Start Date*: 2014-06-17 |
Sponsor Name:Instituto Tecnológico PET, S.A.U. (ITP) | ||
Full Title: A Phase III Clinical Trial to evidence the safety and efficacy of the radio-drug 18f-Fluorocholine (18F-FCH), using Positron Emission Tomography (PET) for the diagnosis of the prostate carcinoma in... | ||
Medical condition: Prostate Carcinoma in patients with biochemical relapse. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005598-30 | Sponsor Protocol Number: HMR4003B/3507 | Start Date*: 2006-04-28 | |||||||||||
Sponsor Name:sanofi-aventis Groupe | |||||||||||||
Full Title: A NON-INVASIVE EVALUATION OF BONE MICROARCHITECTURE MODIFICATION IN OSTEOPENIC POSTMENOPAUSAL WOMEN BY 3D-PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY : A 24-MONTH, MONOCENTER, DOUBLE-BLIND, RANDOMI... | |||||||||||||
Medical condition: Osteopenic postmenopausal women | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004480-31 | Sponsor Protocol Number: ALLOB-IF1 | Start Date*: 2014-05-27 | |||||||||||
Sponsor Name:Bone Therapeutics S.A. | |||||||||||||
Full Title: A Pilot Phase IIa, Multicentre, Open, Proof-of-concept Study on the Safety and the Efficacy of Allogeneic Osteoblastic Cells (ALLOB®) implantation in Lumbar Spinal Fusion | |||||||||||||
Medical condition: Degenerative disc disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000155-21 | Sponsor Protocol Number: UC-0160/1702 | Start Date*: 2019-07-23 | |||||||||||
Sponsor Name:UNICANCER | |||||||||||||
Full Title: An open label, randomized, phase III study, evaluating the efficacy of a Combination of Apalutamide with Radiotherapy and LHRH Agonist in high-risk postprostatectomy biochemically relapsed prostate... | |||||||||||||
Medical condition: High-risk biochemically-relapsed prostate adenocarcinoma following radical prostatectomy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003542-21 | Sponsor Protocol Number: ALADDIN | Start Date*: 2022-02-28 |
Sponsor Name:ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie | ||
Full Title: Evaluation of dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases | ||
Medical condition: Prostate cancer with pelvic lymph nodes metastases. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003275-20 | Sponsor Protocol Number: G-0034 | Start Date*: 2005-10-07 | |||||||||||
Sponsor Name:Cell Genesys Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Open-Label Study of Docetaxel in Combination with CG1940 and CG8711 versus Docetaxel and Prednisone in Taxane-Naïve Patients with Metastatic Hormone-Refractory Prostate Cancer... | |||||||||||||
Medical condition: Metastatic Hormone-Refractory Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) BE (Completed) IT (Prematurely Ended) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-005035-33 | Sponsor Protocol Number: R2477-FOP-1623 | Start Date*: 2017-08-15 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and effects on heterotopic bone formation of REGN2477 in patients with Fibrodysplasia Ossificans Progres... | |||||||||||||
Medical condition: Fibrodysplasia Ossificans Progressiva (FOP) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000123-12 | Sponsor Protocol Number: 2020110469 | Start Date*: 2021-06-22 |
Sponsor Name:Odense University Hospital | ||
Full Title: PRISMA-PET – Primary Staging of Prostate Cancer: A Randomized Controlled Trial Comparing 18F-PSMA-1007 PET/CT to Conventional Imaging. | ||
Medical condition: Newly diagnosed prostate cancer, PET/CT scan used to stage newly diagnosed prostate cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-000422-39 | Sponsor Protocol Number: 8669-002 | Start Date*: 2009-01-14 | |||||||||||
Sponsor Name:MSD | |||||||||||||
Full Title: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide With or Without Deforolimus in Men With Asymptomatic, Metastatic Castrate-Res... | |||||||||||||
Medical condition: Metastatic prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SE (Completed) NL (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) DK (Completed) GB (Prematurely Ended) BE (Completed) DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004794-41 | Sponsor Protocol Number: Vista | Start Date*: 2017-03-02 |
Sponsor Name:Academical medical centre, dep of internal medicine | ||
Full Title: Arterial wall inflammation measured with 18F-FDG PET/CT in patients with statin intolerance before and after treatment with a PCSK-9 inhibitor | ||
Medical condition: Patients with CV-risk and statin intolerance due to statin-associated muscle symptoms (SAMS) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001059-63 | Sponsor Protocol Number: 2015.009 | Start Date*: 2015-09-23 | |||||||||||
Sponsor Name:Aalborg University | |||||||||||||
Full Title: BONATHIAD - Bone Association with Thiazide Diuretics. | |||||||||||||
Medical condition: The effect of bendroflumethiazide with potassium supplement when used as an adjuvant to oral bisphosphonates in the treatment of newly diagnosed osteoporosis among post-menopausal women above 50 ye... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
